View all IQVIA events


The long-anticipated FDA RWE draft guidance documents have been released. This is a critical milestone in advancing the use of real world evidence for regulatory decision making. This expert panel was involved in responding to each of the documents discusses the interpretation and implementation of these draft guidances with respect to study design, data standards and quality, and policy as they consider opportunities for life sciences industry members moving forward.